These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 33830427)
21. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Francobandiera G Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793 [TBL] [Abstract][Full Text] [Related]
22. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Muscatello MR; Bruno A; Pandolfo G; Micò U; Scimeca G; Romeo VM; Santoro V; Settineri S; Spina E; Zoccali RA J Clin Psychopharmacol; 2011 Apr; 31(2):174-9. PubMed ID: 21346614 [TBL] [Abstract][Full Text] [Related]
23. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder. Brakoulias V; Stockings E Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669 [TBL] [Abstract][Full Text] [Related]
24. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Bogetto F; Bellino S; Vaschetto P; Ziero S Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782 [TBL] [Abstract][Full Text] [Related]
25. A Promising Preliminary Study of Aripiprazole for Treatment-Resistant Childhood Obsessive-Compulsive Disorder. Ercan ES; Ardic UA; Ercan E; Yuce D; Durak S J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):580-4. PubMed ID: 26375768 [TBL] [Abstract][Full Text] [Related]
26. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E Eur Neuropsychopharmacol; 2014 Mar; 24(3):375-80. PubMed ID: 24406025 [TBL] [Abstract][Full Text] [Related]
27. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses]. Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085 [TBL] [Abstract][Full Text] [Related]
28. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis. Maiti R; Mishra A; Srinivasan A; Mishra BR Acta Psychiatr Scand; 2023 Jul; 148(1):19-31. PubMed ID: 37177823 [TBL] [Abstract][Full Text] [Related]
29. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Sayyah M; Sayyah M; Boostani H; Ghaffari SM; Hoseini A Depress Anxiety; 2012 Oct; 29(10):850-4. PubMed ID: 22933237 [TBL] [Abstract][Full Text] [Related]
30. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. Veale D; Miles S; Smallcombe N; Ghezai H; Goldacre B; Hodsoll J BMC Psychiatry; 2014 Nov; 14():317. PubMed ID: 25432131 [TBL] [Abstract][Full Text] [Related]
31. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. Marazziti D; Pfanner C; Dell'Osso B; Ciapparelli A; Presta S; Corretti G; Di Nasso E; Mungai F; Dell'Osso L J Psychopharmacol; 2005 Jul; 19(4):392-4. PubMed ID: 15982994 [TBL] [Abstract][Full Text] [Related]